Vivoryon Therapeutics N.V. (VVY), a clinical stage company developing small molecule medicines for pathologically altered proteins, has announced two upcoming events in September 2024:
1. Half Year 2024 Results on September 12, 2024, at 3:00 pm CEST / 9:00 am EDT. The company will publish financial results and provide a corporate update. A conference call and webcast will be available to the public.
2. Virtual Kidney Disease KOL Event on September 30, 2024, at 3:00 pm CEST / 9:00 am EDT. Further details and participation information will be provided on the company's website.
Both events will be accessible via webcast on Vivoryon's website. For the half-year results call, participants can pre-register for dial-in details.
Vivoryon Therapeutics N.V. (VVY) announced new data showing unique treatment effects of varoglutamstat on kidney function in patients with diabetes. The company reported a significant treatment effect of >8mL/min/1.73m2/year in estimated glomerular filtration rate (eGFR) in the diabetes subgroup of the VIVIAD Phase 2b study. This effect was substantially higher than the 3.4mL/min/1.73m2/year observed in the overall study population.
Additional benefits observed in the diabetes subgroup included weight loss, reduced diastolic blood pressure, and decreased liver enzymes. Varoglutamstat demonstrated an excellent tolerability profile with no meaningful difference in adverse events between the overall population and the diabetes subgroup.
Vivoryon also outlined a proposed Phase 2 clinical development plan for varoglutamstat in diabetic kidney disease (DKD), targeting patients with more advanced disease stages.
Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) will host an R&D update call on July 18, 2024, at 3:00 pm CEST / 9:00 am EDT, focusing on advancements in kidney disease treatment. The conference will detail further analyses and data on varoglutamstat's beneficial effects on kidney function, along with updates on its clinical development plan. Participants can join via phone or webcast, with a live audio stream available on Vivoryon's website. The event will include a Q&A session for investors and analysts. Pre-registration is required for phone access, and a replay will be available post-presentation.
Vivoryon Therapeutics N.V., a clinical-stage company focused on small molecule medicines, held its 2024 Annual General Meeting (AGM) on June 21 in Halle (Saale) / Munich, Germany. Shareholders approved all proposed items on the agenda. The event, held at 1:00 p.m. (CEST), included a presentation by the management team. Key details and related documents regarding the AGM are accessible on the company's website.
Vivoryon Therapeutics N.V. reported financial results for Q1 2024, highlighting a strategic shift towards kidney disease following disappointing AD study results. The company observed substantial improvements in kidney function with varoglutamstat. Revenue remained zero, but R&D and administrative expenses rose, leading to a net loss of EUR 9.3 million. Cash reserves stood at EUR 22.0 million, expected to fund operations into Q2 2025. Vivoryon will focus on inflammatory and fibrotic disorders and plans to discontinue the VIVA-MIND study. The 2024 Annual General Meeting is set for June 21 in Amsterdam.
Vivoryon Therapeutics N.V. (VVY) has announced it will report its Q1 2024 financial results and provide an operational update on May 23, 2024. The clinical-stage company, known for developing small molecule medicines targeting altered proteins, will host a public conference call and webcast at 3:00 pm CEST / 9:00 am EDT on the same day.
The webcast will be available on Vivoryon's website, and participants can register for the call in advance to receive dial-in details. Interested parties are encouraged to join the call 15 minutes early to avoid delays.
Vivoryon Therapeutics N.V. will hold its 2024 Annual General Meeting on June 21, 2024, focusing on the discovery and development of small molecule medicines to modulate pathologically altered proteins. The meeting will take place in Amsterdam with relevant documents accessible on the company's website.
Summary not available.
Summary not available.
Summary not available.